Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Technology appraisal guidance
Reference number: TA414
Published: 26 October 2016

Evidence

Supporting evidence

Review decision
Review decision – October 2020
Review decision paper (PDF 159 KB)

Published:

09 October 2020